Miami Genitorinary (GU) Oncology Summit

Miami Genitorinary (GU) Oncology Summit is organized by Binaytara Foundation (BTF) and will be held on Nov 14, 2026 at Hyatt Regency Miami, Miami, Florida, United States of America.

Description:
The 2026 Miami GU Oncology Summit is an annual, clinically focused conference dedicated to advancing the diagnosis and management of genitourinary (GU) cancers, including prostate, bladder, kidney, and testicular malignancies. This educational meeting brings together leading experts and healthcare professionals to review the latest clinical evidence, treatment innovations, and multidisciplinary care strategies in GU oncology.

The summit will feature a robust program of expert-led didactic sessions, multidisciplinary panel discussions, and interactive case-based learning designed to enhance clinical decision-making and improve patient outcomes. Participants will gain insights into emerging therapies, precision oncology, immunotherapy, and evolving standards of care, with a focus on translating research into real-world practice.

Key topics will include risk stratification, biomarker-driven treatment selection, management of advanced and metastatic disease, treatment sequencing, and survivorship care. Case-based sessions will highlight complex and controversial scenarios, enabling participants to apply evidence-based approaches in diverse clinical settings.

This conference emphasizes practical, patient-centered care and interdisciplinary collaboration, equipping clinicians with the knowledge and tools needed to optimize outcomes for patients with GU malignancies.

Learning Objectives:

1. Evaluate current and emerging treatment strategies for prostate, bladder, kidney, and other GU cancers.
2. Incorporate biomarker-driven and precision oncology approaches into the management of GU malignancies.
3. Develop individualized, evidence-based treatment plans across the spectrum of localized and advanced disease.
4. Analyze complex clinical cases to improve therapeutic decision-making and sequencing of treatments.
5. Integrate multidisciplinary care approaches, including medical, surgical, and radiation oncology, to optimize patient outcomes.